A randomized hypofractionation dose escalation trial for high risk prostate cancer patients: Interim analysis of acute toxicity and quality of life in 124 patients

Radiation Oncology

Volumn 8, Issue 1, 2013, Pages

  Norkus, Darius ^a   Karklelyte, Agata ^a   Engels, Benedikt ^b   Versmessen, Harijati ^b   Griskevicius, Romas ^a   De Ridder, Mark ^b   Storme, Guy ^b   Aleknavicius, Eduardas ^a   Janulionis, Ernestas ^a   Valuckas, Konstantinas P ^a  

^a VILNIUS UNIVERSITY   (Lithuania)

^b UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BLADDER; FOLLOW UP; GASTROINTESTINAL TOXICITY; GLEASON SCORE; HIGH RISK PATIENT; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MAJOR CLINICAL STUDY; MALE; PELVIS LYMPH NODE; PROSTATE ADENOCARCINOMA; QUALITY OF LIFE; RADIATION DOSE ESCALATION; RADIATION DOSE FRACTIONATION; RADIATION INJURY; RECTUM; TRANSURETHRAL RESECTION; URINE INCONTINENCE; UROGENITAL TRACT DISEASE; ADENOCARCINOMA; CLINICAL TRIAL; CONTROLLED STUDY; IMAGE GUIDED RADIOTHERAPY; MIDDLE AGED; PHASE 3 CLINICAL TRIAL; PROSTATIC NEOPLASMS; RADIATION RESPONSE; RANDOMIZED CONTROLLED TRIAL;

ADENOCARCINOMA; AGED; DOSE FRACTIONATION; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; QUALITY OF LIFE; RADIOTHERAPY, IMAGE-GUIDED; RADIOTHERAPY, INTENSITY-MODULATED;

EID: 84883290461     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-8-206     Document Type: Article

References (26)

1. Kuban DA, Tucker SL, Dong L, Starkschall G, Huang EH, Cheung MR, et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2008, 70:67-74. 10.1016/j.ijrobp.2007.06.054, 17765406.
2. Cahlon O, Zelefsky MJ, Shippy A, Chan H, Fuks Z, Yamada Y, et al. Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes. Int J Radiat Oncol Biol Phys 2008, 71:330-337. 10.1016/j.ijrobp.2007.10.004, 18164858.
3. Norkus D, Miller A, Kurtinaitis J, et al. A randomized trial comparing hypofractionated and conventionally fractionated three-dimensional external-beam radiotherapy for localized prostate adenocarcinoma : a report on acute toxicity. Strahlenther Onkol 2009, 185:715-721. 10.1007/s00066-009-1982-z, 19899003.
4. Arcangeli G, Fowler J, Gomellini S, et al. Acute and late toxicity in a randomized trial of conventional versus hypofractionated three-dimensional conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2011, 79:1013-1021. 10.1016/j.ijrobp.2009.12.045, 20447774.
5. Kupelian PA, Reddy CA, Klein EA, et al. Short-course intensity-modulated radiotherapy (70 GY at 2.5 GY per fraction) for localized prostate cancer: preliminary results on late toxicity and quality of life. Int J Radiat Oncol Biol Phys 2001, 51:988-993. 10.1016/S0360-3016(01)01730-8, 11704322.
6. Coote JH, Wylie JP, Cowan RA, et al. Hypofractionated intensity-modulated radiotherapy for carcinoma of the prostate: analysis of toxicity. Int J Radiat Oncol Biol Phys 2009, 74:1121-1127. 10.1016/j.ijrobp.2008.09.032, 19131179.
7. Katz A, Ferrer M, Suarez JF. Multicentric Spanish Group of Clinically Localized Prostate Cancer Comparison of quality of life after stereotactic body radiotherapy and surgery for early-stage prostate cancer. Radiat Oncol 2012, 7:194. 10.1186/1748-717X-7-194, 3528663, 23164305, Multicentric Spanish Group of Clinically Localized Prostate Cancer.
8. Katz AJ, Santoro M, Diblasio F, et al. Stereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6 years. Radiat Oncol 2013, 8:118. 10.1186/1748-717X-8-118, 3674983, 23668632.
9. Quon H, Cheung PC, Loblaw DA, et al. Quality of life after hypofractionated concomitant intensity-modulated radiotherapy boost for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2012, 83:617-623.
10. Pervez N, Krauze AV, Yee D, et al. Quality-of-life outcomes in high-risk prostate cancer patients treated with helical tomotherapy in a hypofractionated radiation schedule with long-term androgen suppression. Current oncology 2012, 19:201-210.
11. Miralbell R, Roberts SA, Zubizarreta E, et al. Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: alpha/beta = 1.4 (0.9-2.2) Gy. Int J Radiat Oncol Biol Phys 2012, 82:17-24.
12. Sanguineti G, Cavey ML, Endres EJ, et al. Is IMRT needed to spare the rectum when pelvic lymph nodes are part of the initial treatment volume for prostate cancer?. Int J Radiat Oncol Biol Phys 2006, 64:151-160. 10.1016/j.ijrobp.2005.06.026, 16198066.
13. Litwin MS, Lubeck DP, Henning JM, et al. Differences in urologist and patient assessments of health related quality of life in men with prostate cancer: results of the CaPSURE database. J Urol 1998, 159:1988-1992. 10.1016/S0022-5347(01)63222-1, 9598504.
14. Eade TN, Hanlon AL, Horwitz EM, et al. What dose of external-beam radiation is high enough for prostate cancer?. Int J Radiat Oncol Biol Phys 2007, 68:682-689. 10.1016/j.ijrobp.2007.01.008, 2770596, 17398026.
15. Fowler J, King CR. Don't Squeeze hypofractionated schedules into Too-short overall times. Int J Radiat Oncol Biol Phys 2009, 75:323-325. 10.1016/j.ijrobp.2009.06.022, 19735858.
16. Lawton CA, Michalski J, El-Naqa I, et al. RTOG GU Radiation oncology specialists reach consensus on pelvic lymph node volumes for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2009, 74:383-387. 10.1016/j.ijrobp.2008.08.002, 2905150, 18947938.
17. De Meerleer G, Vakaet L, Meersschout S, et al. Intensity-modulated radiotherapy as primary treatment for prostate cancer: acute toxicity in 114 patients. Int J Radiat Oncol Biol Phys 2004, 60:777-787. 10.1016/j.ijrobp.2004.04.017, 15465194.
18. Wei JT, Dunn RL, Litwin MS, et al. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology 2000, 56:899-905. 10.1016/S0090-4295(00)00858-X, 11113727.
19. Madsen BL, Hsi RA, Pham HT, et al. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results. Int J Radiat Oncol Biol Phys 2007, 67:1099-1105. 10.1016/j.ijrobp.2006.10.050, 17336216.
20. Kupelian PA, Willoughby TR, Reddy CA, et al. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: cleveland clinic experience. Int J Radiat Oncol Biol Phys 2007, 68:1424-1430. 10.1016/j.ijrobp.2007.01.067, 17544601.
21. Dearnaley D, Syndikus I, Sumo G, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncol 2012, 13:43-54. 10.1016/S1470-2045(11)70293-5, 22169269.
22. Arcangeli S, Saracino B, Petrongari MG, et al. Analysis of toxicity in patients with high risk prostate cancer treated with intensity-modulated pelvic radiation therapy and simultaneous integrated dose escalation to prostate area. Radiother Oncol 2007, 84:148-155. 10.1016/j.radonc.2007.06.011, 17692416.
23. Chung HT, Xia P, Chan LW, et al. Does image-guided radiotherapy improve toxicity profile in whole pelvic-treated high-risk prostate cancer? Comparison between IG-IMRT and IMRT. Int J Radiat Oncol Biol Phys 2009, 73:53-60. 10.1016/j.ijrobp.2008.03.015, 18501530.
24. Pervez N, Small C, MacKenzie M, Yee D, et al. Acute toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 2010, 76:57-64. 10.1016/j.ijrobp.2009.01.048, 19395192.
25. Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008, 358:1250-1261. 10.1056/NEJMoa074311, 18354103.
26. Boike TP, Lotan Y, Cho LC, et al. Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer. J Clin Oncol 2011, 29:2020-2026. 10.1200/JCO.2010.31.4377, 3138546, 21464418.